ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
157.25 EUR
+1.3 (+0.83%)
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 52 industry peers in the Pharmaceuticals industry. ZEG has an excellent profitability rating, but there are concerns on its financial health. ZEG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
ZEG had a positive operating cash flow in the past year.
Each year in the past 5 years ZEG has been profitable.
ZEG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ZEG has a better Return On Assets (8.21%) than 66.67% of its industry peers.
ZEG's Return On Equity of 20.48% is fine compared to the rest of the industry. ZEG outperforms 70.37% of its industry peers.
ZEG has a better Return On Invested Capital (14.42%) than 72.22% of its industry peers.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 13.72%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
ZEG has a Profit Margin of 16.17%. This is in the better half of the industry: ZEG outperforms 66.67% of its industry peers.
ZEG's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 24.34%, ZEG is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
ZEG's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 81.90%, ZEG belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
ZEG has more shares outstanding than it did 5 years ago.
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
ZEG has an Altman-Z score of 6.03. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.03, ZEG belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.41, ZEG is in line with its industry, outperforming 59.26% of the companies in the same industry.
ZEG has a Debt/Equity ratio of 0.61. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio of 0.61. This is comparable to the rest of the industry: ZEG outperforms 46.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6.03 |
ROIC/WACC1.58
WACC9.11%
2.3 Liquidity
A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
The Current ratio of ZEG (0.88) is worse than 81.48% of its industry peers.
ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a worse Quick ratio (0.69) than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
ZEG shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.45% on average per year.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.29, the valuation of ZEG can be described as rather expensive.
The rest of the industry has a similar Price/Earnings ratio as ZEG.
When comparing the Price/Earnings ratio of ZEG to the average of the S&P500 Index (26.92), we can say ZEG is valued slightly cheaper.
The Price/Forward Earnings ratio is 17.82, which indicates a rather expensive current valuation of ZEG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZEG is on the same level as its industry peers.
ZEG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 17.82 |
4.2 Price Multiples
68.52% of the companies in the same industry are cheaper than ZEG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ZEG is valued a bit more expensive than 64.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.07 | ||
| EV/EBITDA | 28.85 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)1.09
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.63%, ZEG has a reasonable but not impressive dividend return.
ZEG's Dividend Yield is a higher than the industry average which is at 2.20.
Compared to an average S&P500 Dividend Yield of 2.00, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.89% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
FRA:ZEG (12/23/2025, 7:00:00 PM)
157.25
+1.3 (+0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap487.56B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target166.38 (5.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend2.53
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)3.89%
PT rev (3m)6.22%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.29 | ||
| Fwd PE | 17.82 | ||
| P/S | 9.89 | ||
| P/FCF | 60.07 | ||
| P/OCF | 37.96 | ||
| P/B | 12.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.85 |
EPS(TTM)7.75
EY4.93%
EPS(NY)8.82
Fwd EY5.61%
FCF(TTM)2.62
FCFY1.66%
OCF(TTM)4.14
OCFY2.63%
SpS15.91
BVpS12.56
TBVpS-3.7
PEG (NY)1.7
PEG (5Y)1.09
Graham Number46.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6.03 |
F-Score7
WACC9.11%
ROIC/WACC1.58
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.29 and the Price/Book (PB) ratio is 12.52.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.